Evidence map›Paper›PMID 25978818›Full record

ArticlePloS one2015

A Lipopolysaccharide from Pantoea Agglomerans Is a Promising Adjuvant for Sublingual Vaccines to Induce Systemic and Mucosal Immune Responses in Mice via TLR4 Pathway.

Masahiro Fukasaka, Daisuke Asari, Eiji Kiyotoh, Arimichi Okazaki, Yasuyuki Gomi, Takeshi Tanimoto, Osamu Takeuchi, Shizuo Akira, Mitsuhiko Hori

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 27 citations in OpenAlex.

  1. [Oral mucosal administration].Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Maintenance of homeostasis by TLR4 ligands.Frontiers in immunology · 2024
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Masahiro FukasakaLife Science Research Center, Corporate Research & Development Division, Nitto Denko Corporation, Ibaraki, Osaka, Japan.
Daisuke AsariLife Science Research Center, Corporate Research & Development Division, Nitto Denko Corporation, Ibaraki, Osaka, Japan.
Eiji KiyotohLife Science Research Center, Corporate Research & Development Division, Nitto Denko Corporation, Ibaraki, Osaka, Japan.
Arimichi OkazakiLife Science Research Center, Corporate Research & Development Division, Nitto Denko Corporation, Ibaraki, Osaka, Japan.
Yasuyuki GomiResearch and Production Technology Department, The Research Foundation for Microbial Diseases of Osaka University, Kanonji, Kagawa, Japan.
Takeshi TanimotoResearch and Production Technology Department, The Research Foundation for Microbial Diseases of Osaka University, Kanonji, Kagawa, Japan.
Osamu TakeuchiLaboratory of Infection and Prevention, Institute for Virus Research, Kyoto University, Shogoin Kawara-cho, Sakyo-ku, Kyoto, Japan.
Shizuo AkiraLaboratory of Host Defense, WPI Immunology Frontier Research Center (IFReC), Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Mitsuhiko HoriLife Science Research Center, Corporate Research & Development Division, Nitto Denko Corporation, Ibaraki, Osaka, Japan.
Nitto (Japan) · JPOsaka University · JPKyoto University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A lipopolysaccharide from Pantoea agglomerans (LPSpa) has been applied to various fields for human use as a Toll-like receptor 4 ligand and its safety has been confirmed. Here, we showed for the first time the application of LPSpa as an effective mucosal adjuvant for activating vaccine-induced antigen specific immune responses. Mice sublingually immunized with influenza vaccine (HA split vaccine) with LPSpa induced both HA-specific IgG (systemic) and IgA (mucosal) antibody responses, which led to a significant increase in survival rate against lethal influenza virus challenge compared with subcutaneous vaccination. After sublingual administration of ovalbumin with LPSpa, ovalbumin-specific mucosal IgA responses were induced at both mucosal surfaces close to the immunized site and at remote mucosal surfaces. Sublingual administration of LPSpa evoked local antigen-uptake by dendritic cells in cervical lymph nodes. LPSpa induced cytokine production and the maturation and proliferation of innate immune cells via Toll-like receptor 4 in dendritic cells. Collectively, these results suggest that LPSpa can be used as an effective mucosal adjuvant to stimulate and activate local innate immune cells to improve and enhance mucosal vaccine potency against various pathogens.

Indexed as

Adjuvants, ImmunologicAdministration, SublingualAnimalsEnzyme-Linked Immunosorbent AssayFemaleImmunity, HumoralImmunity, MucosalImmunoglobulin AImmunoglobulin GInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza VaccinesLipopolysaccharidesMiceMice, Inbred BALB CMice, Inbred C57BLAdjuvants, ImmunologicImmunoglobulin AImmunoglobulin GInfluenza VaccinesLipopolysaccharidesTlr4 protein, mouseToll-Like Receptor 4

Identifiers

PMID25978818
PMCPMC4433252
OpenAlexW1555399818

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.